Phase 4 Non-Alcoholic Fatty Liver Disease Trial, Recruiting NCT06449833 Sponsor: Zhujiang Hospital Condition: Non-Alcoholic Fatty Liver Disease
Back to Non Alcoholic Fatty Liver Disease

Phase 4 Non-Alcoholic Fatty Liver Disease Trial, Recruiting

NCT06449833
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with type 2 diabetes within the last 5 years
  • You are willing to take part, understand what the trial involves, and are happy to sign a consent form and follow all study requirements
  • Your blood sugar is managed either through diet and exercise alone, or you have been on one or two diabetes medications (from a specific approved list) at a stable dose for at least 8 weeks
  • Your HbA1c (a measure of average blood sugar over roughly 3 months) is between 7.0% and 8.5%
  • You have also been diagnosed with non-alcoholic fatty liver disease (a condition where fat builds up in the liver, not caused by alcohol)

Who may not be able to join:

  • You have type 1 diabetes, diabetes related to pregnancy, or another specific type of diabetes
  • You have had a serious diabetes complication in the past 6 months, such as dangerously high blood sugar requiring emergency care
  • You have had serious eye, nerve, circulation, or foot problems related to diabetes in the past 6 months
  • You have serious liver disease, advanced kidney disease, or other significant conditions such as pancreatitis or liver cirrhosis
  • You had a heart attack, unstable chest pain, stroke, or a major heart procedure in the past 6 months, or you have advanced heart failure or a life-threatening irregular heartbeat
  • You have had a bleeding or blockage stroke in the past 6 months that researchers feel makes participation unsuitable
  • You have high blood pressure that is not well controlled (readings at or above 160/100 mmHg)
  • You have a hormonal condition (other than diabetes) that affects your weight, blood sugar, or fats in the blood, such as an overactive thyroid or Cushing's syndrome
  • You have been diagnosed with a cancer (other than a treated skin basal cell carcinoma) in the past 5 years
  • You have had a serious infection, major injury, or major surgery in the past 3 months
  • You have a history of substance or drug misuse in the past 5 years
  • You have taken part in another clinical drug or device trial in the past 3 months
  • You have severe anaemia or need regular blood transfusions
  • You have taken medications that affect your weight (such as water tablets or weight-loss drugs) in the past 90 days
  • You have taken medications that significantly affect blood sugar for more than 1 week in the past 12 weeks (such as steroid tablets, growth hormone, or certain antipsychotic medications) — note that low-dose blood pressure water tablets may be allowed (confirm with trial site)
  • You have had weight-loss (bariatric) surgery or are planning to have it
  • Your liver enzyme levels (ALT/AST) are more than 5 times higher than the normal upper limit
  • Your kidney filtering function is significantly reduced (eGFR below 40, measured by a specific formula)
  • You are currently pregnant, breastfeeding, or planning to become pregnant
  • You have a history of hepatitis B, hepatitis C, tuberculosis, HIV, or syphilis
  • You have taken certain liver-related treatments (such as vitamin E, ursodeoxycholic acid, or similar drugs) within the past 3 months
  • You have a structural or functional problem with your urinary or reproductive system that makes infections more likely
  • You have a blood or red blood cell disorder
  • You have taken immune-suppressing medications such as cyclosporine or cyclophosphamide
  • You have metal implants or devices in your body that are not compatible with MRI scanning

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Hong Chen, MD, Zhujiang Hospital

Phone: 13602759769

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Zhujiang Hospital
Registry
ClinicalTrials.gov
Start date
1 June 2024
Est. completion
1 November 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The difference of liver fat content (magnetic resonance imaging proton density fat fraction,MRI-PDFF)) between the subjects and the control group.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov